- Home
- CLBT vs ARQT Comparison
CLBT vs ARQT Comparison
Compare CLBT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLBT | ARQT |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLBT | ARQT |
|---|---|---|
| Price | $14.94 | $26.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $24.40 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $455,903,000.00 | $317,929,000.00 |
| Revenue This Year | $20.27 | $86.38 |
| Revenue Next Year | $17.29 | $30.29 |
| P/E Ratio | $46.81 | ★ N/A |
| Revenue Growth | 18.36 | ★ 129.21 |
| 52 Week Low | $13.10 | $11.13 |
| 52 Week High | $25.87 | $31.77 |
Technical Indicators
Market Signals| Indicator | CLBT | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 51.19 |
| Support Level | $13.54 | $24.50 |
| Resistance Level | $16.89 | $27.62 |
| Average True Range (ATR) | 0.68 | 0.95 |
| MACD | -0.06 | 0.19 |
| Stochastic Oscillator | 41.88 | 79.47 |
Price Performance
Historical ComparisonAbout CLBT Cellebrite DI Ltd.
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.